Literature DB >> 11278258

Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing.

D Rigamonti1, S Sipione, D Goffredo, C Zuccato, E Fossale, E Cattaneo.   

Abstract

Huntington's Disease is an inherited neurodegenerative disease that affects the medium spiny neurons in the striatum. The disease is caused by the expansion of a polyglutamine sequence in the N terminus of Huntingtin (Htt), a widely expressed protein. Recently, we have found that Htt is an antiapoptotic protein in striatal cells and acts by preventing caspase-3 activity. Here we report that Htt overexpression in other CNS-derived cells can protect them from more than 20 days exposure to fatal stimuli. In particular, we found that cytochrome c continues to be released from mitochondria into the cytosol of cells that overexpress normal Htt. However, procaspase-9 is not processed, indicating that wild-type Htt (wtHtt) acts downstream of cytochrome c release. These data show that Htt inhibits neuronal cell death by interfering with the activity of the apoptosome complex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278258     DOI: 10.1074/jbc.C100044200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Regulation of RE1 protein silencing transcription factor (REST) expression by HIP1 protein interactor (HIPPI).

Authors:  Moumita Datta; Nitai P Bhattacharyya
Journal:  J Biol Chem       Date:  2011-08-06       Impact factor: 5.157

Review 3.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

Review 4.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 5.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

6.  Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease.

Authors:  Xin Wang; Shan Zhu; Zhijuan Pei; Martin Drozda; Irina G Stavrovskaya; Steven J Del Signore; Kerry Cormier; Ethan M Shimony; Hongyan Wang; Robert J Ferrante; Bruce S Kristal; Robert M Friedlander
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

7.  A systems biology analysis of apoptosome formation and apoptosis execution supports allosteric procaspase-9 activation.

Authors:  Maximilian L Würstle; Markus Rehm
Journal:  J Biol Chem       Date:  2014-08-08       Impact factor: 5.157

8.  Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway.

Authors:  Hemant Varma; Ai Yamamoto; Melissa R Sarantos; Robert E Hughes; Brent R Stockwell
Journal:  J Biol Chem       Date:  2010-09-21       Impact factor: 5.157

Review 9.  Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases.

Authors:  A Cristina Rego; Catarina R Oliveira
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

10.  Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures.

Authors:  Robert P Lisak; Joyce A Benjamins; Beverly Bealmear; Liljana Nedelkoska; Diane Studzinski; Ernest Retland; Bin Yao; Susan Land
Journal:  J Neuroinflammation       Date:  2009-01-21       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.